בדיקת ממהפרינט
הערות שוליים

1 2 3  Fatima Cardoso, Laura J. van’t Veer, Jan Bogaerts, Leen Slaets, 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer, New England Journal of Medicine 375, 2016-08-24, עמ' 717–729 doi: 10.1056/nejmoa1602253
↑  Laura J. van 't Veer, Hongyue Dai, Marc J. van de Vijver, Yudong D. He, Gene expression profiling predicts clinical outcome of breast cancer, Nature 415, עמ' 530–536 doi: 10.1038/415530a
↑  Richard M. Simon, Soonmyung Paik, Daniel F. Hayes, Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers, JNCI Journal of the National Cancer Institute 101, 2009-11-04, עמ' 1446–1452 doi: 10.1093/jnci/djp335
↑  CA Drukker, JM Bueno-de-Mesquita, VP Retèl, WH van Harten, A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study, International Journal of Cancer. Journal International du Cancer 133, 2013-08-15, עמ' 929–936 doi: 10.1002/ijc.28082
↑  Hormone Therapy for Breast Cancer, www.cancer.org
↑  S. Mook, M. K. Schmidt, B. Weigelt, B. Kreike, The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age, Annals of Oncology: Official Journal of the European Society for Medical Oncology 21, April 2010, עמ' 717–722 doi: 10.1093/annonc/mdp388
↑  Ben S. Wittner, Dennis C. Sgroi, Paula D. Ryan, Tako J. Bruinsma, Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort, Clinical cancer research : an official journal of the American Association for Cancer Research 14, 2008-05-15, עמ' 2988–2993 doi: 10.1158/1078-0432.CCR-07-4723
↑  Unbiased gene selection, based on patient outcomes | Agendia, www.agendia.com (באנגלית) (ארכיון)
↑  Marc J. van de Vijver, Yudong D. He, Laura J. van 't Veer, Hongyue Dai, A Gene-Expression Signature as a Predictor of Survival in Breast Cancer, New England Journal of Medicine 347, 2002-12-19, עמ' 1999–2009 doi: 10.1056/NEJMoa021967
↑  Laura J. van 't Veer, Hongyue Dai, Marc J. van de Vijver, Yudong D. He, Gene expression profiling predicts clinical outcome of breast cancer, Nature 415, 2002-01-31, עמ' 530–536 doi: 10.1038/415530a
↑  Schattner, Elaine. "MammaPrint, Agendia's Breast Cancer Test, Is Having A U.S. Moment. Can It Reduce Overtreatment?". Forbes (באנגלית). נבדק ב-2017-09-03.
↑  Agendia, Agendia's MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines, www.prnewswire.com (באנגלית)
↑  "St. Gallen's Recommendations May Impact Adoption of Leading Breast Cancer Genetic Tests". GenomeWeb (באנגלית). נבדק ב-2017-09-03.
↑  "Agendia MammaPrint Given Highest Level Evidence Label in Breast Cancer Guidelines". GenomeWeb (באנגלית). נבדק ב-2017-09-03.
↑  M. J. Duffy, N. Harbeck, M. Nap, R. Molina, Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM), European Journal of Cancer 75, 2017-04-01, עמ' 284–298 doi: 10.1016/j.ejca.2017.01.017
↑  "European Group Gives Highest Level Label to Agendia MammaPrint". GenomeWeb (באנגלית). נבדק ב-2017-09-03.
↑  Office of the Commissioner, Consumer Updates - Test Determines Risk of Breast Cancer Returning, www.fda.gov (באנגלית)
↑  Agendia Awarded Level 1 CPT Code for MammaPrint | Agendia, www.agendia.com (באנגלית) (ארכיון)
↑  Inès Beumer, Anke Witteveen, Leonie Delahaye, Diederik Wehkamp, Equivalence of MammaPrint array types in clinical trials and diagnostics, Breast Cancer Research and Treatment 156, 2016, עמ' 279–287 doi: 10.1007/s10549-016-3764-5
↑  Miguel Ángel Seguí, Carlos Crespo, Javier Cortés, Ana Lluch, Genomic profile of breast cancer: cost–effectiveness analysis from the Spanish National Healthcare System perspective, Expert Review of Pharmacoeconomics & Outcomes Research 14, 2014-12-01, עמ' 889–899 doi: 10.1586/14737167.2014.957185
↑   Reed, Shelby D.; Lyman, Gary H. (2012-12-15). "Cost effectiveness of gene expression profiling for early stage breast cancer". Cancer. 118 (24): 6298–6299. doi:10.1002/cncr.27665. ISSN 1097-0142.
↑  Fatima Cardoso, Martine Piccart-Gebhart, Laura Van't Veer, Emiel Rutgers, The MINDACT trial: The first prospective clinical validation of a genomic tool, Molecular Oncology 1, 2007-12, עמ' 246–251 doi: 10.1016/j.molonc.2007.10.004
↑  Fatima Cardoso, Laura Van't Veer, Emiel Rutgers, Sherene Loi, Clinical Application of the 70-Gene Profile: The MINDACT Trial, Journal of Clinical Oncology 26, 2008-02-10, עמ' 729–735 doi: 10.1200/jco.2007.14.3222
הבהרה: המידע בוויקיפדיה נועד להעשרה בלבד ואינו מהווה ייעוץ רפואי.